Rafferty Asset Management, LLC Vaxart, Inc. Transaction History

Rafferty Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$2.09 - $4.5 $1.08 Million - $2.33 Million	517,359 Added 96.27%	1,054,779 $2.3 Million
Q2 2022 Aug 12, 2022	SELL	$2.7 - $5.28 $1.24 Million - $2.42 Million	-459,035 Reduced 46.07%	537,420 $1.88 Million
Q1 2022 May 13, 2022	BUY	$4.29 - $6.64 $637,841 - $987,241	148,681 Added 17.54%	996,455 $5.02 Million
Q4 2021 Feb 10, 2022	BUY	$5.77 - $7.96 $2.84 Million - $3.92 Million	492,066 Added 138.33%	847,774 $5.32 Million
Q3 2021 Nov 10, 2021	BUY	$6.67 - $9.8 $381,870 - $561,069	57,252 Added 19.18%	355,708 $2.83 Million
Q2 2021 Aug 10, 2021	SELL	$5.06 - $10.78 $991,167 - $2.11 Million	-195,883 Reduced 39.63%	298,456 $2.24 Million
Q1 2021 May 10, 2021	BUY	$5.64 - $23.33 $2.08 Million - $8.61 Million	369,042 Added 294.53%	494,339 $2.99 Million
Q4 2020 Feb 10, 2021	BUY	$3.5 - $7.98 $438,539 - $999,870	125,297 New	125,297 $715,000

110

37.6M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $73.4M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.